Lipid-based nutrient supplements do not decrease breast milk intake of Malawian infants
Chiza Kumwenda, Kathryn G Dewey, Jaimie Hemsworth, Per Ashorn, Kenneth Maleta, Marjorie J Haskell, Chiza Kumwenda, Kathryn G Dewey, Jaimie Hemsworth, Per Ashorn, Kenneth Maleta, Marjorie J Haskell
Abstract
Background: The potential for small-quantity lipid-based nutrient supplements (LNS) to promote growth and development after 6 mo of age is currently being investigated. Because infants self-regulate energy intake, consumption of LNS may reduce breast milk intake and potentially decrease the beneficial effects of breast milk.
Objective: The objective was to test the hypothesis that the breast milk intake of 9- to 10-mo-old rural Malawian infants receiving LNS would not be lower than that of infants receiving no supplementation.
Design: This was a substudy of the International Lipid-based Nutrient Supplements (iLiNS) DOSE trial, in which 6-mo-old infants were randomly assigned to receive 10, 20, or 40 g LNS/d containing 56, 117, or 241 kcal/d, respectively, or no LNS until 18 mo of age. A subset was randomly selected to estimate breast milk intake at 9-10 mo of age with the dose-to-mother deuterium oxide dilution method. The noninferiority margin was <10% of total energy requirements.
Results: Baseline characteristics (n = 376) were similar across groups. The mean (± SD) daily breast milk intake of unsupplemented infants was 730 ± 226 g. The differences (95% CIs) in mean intake of infants provided with 10, 20, or 40 g LNS/d, compared with controls, were +62 (-18, +143), +30 (-40, +99), and +2 (-68, +72) g/d, respectively. Non-breast milk oral water intake did not differ by group (P = 0.39) and was inversely (r = -0.22, P < 0.01) associated with breast milk intake.
Conclusion: In this rural Malawian population, breast milk intake at 9-10 mo of age was not reduced by supplementation with complementary foods with 10-40 g LNS/d.
Trial registration: ClinicalTrials.gov NCT00945698.
Source: PubMed
Próximos ensaios clínicos
-
NCT07904767Ainda não está recrutando
-
NCT07931924Ainda não está recrutandoIncontinencia urinaria | Bexiga Neurogênica | Derivação Urinária | Malignidade Pélvica | Carcinoma de Bexiga Urinária
-
NCT07932964RecrutamentoAudição normal | Exposição ao Ruído | Preferred Loudness Level
-
NCT07933419Ainda não está recrutandoCarcinoma de Células Renais de Células Claras | Cancro do ovário | Outros Tumores Sólidos Avançados
-
NCT07931144Ainda não está recrutandoEnterocolite necrotizante do recém-nascido | Sepse Neonatal de Início Tardio
-
NCT07889232Ainda não está recrutandoCâncer de Pulmão de Células Não Pequenas Metastático | Cancer-Associated Weight Loss | Elevated Inflammatory Markers
-
NCT07931534Ainda não está recrutandoHipertrofia | Amigdalectomia | Obstrução das Vias Aéreas Superior | Cirurgia de Adenoidectomia
-
NCT07933536Ainda não está recrutandoPsoríase moderada a grave
-
NCT07930793RecrutamentoAnemia aplástica | Hematopoiese Clonal | Terapia imunossupressora
-
NCT07933185RecrutamentoCistos Mandibulares | Alveolar Bone Defects
-
NCT07932535Ainda não está recrutando
-
NCT07933211Ainda não está recrutando